Igc Pharma Inc 's ability to collect accounts receivable sequentially worsen to 2.94, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Igc Pharma Inc 's Accounts Receivable average collection period in the Sep 30 2026 quarter, has increased to 124 days, from 68 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 50 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 579, from overall ranking in the second quarter 2026 at 2546.

What is Receivable Turnover Ratio?
What is Igc Pharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IGC Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Receivable Change	1651.22 %	716.09 %	8.82 %	-95.33 %	-6.82 %
Y / Y Revenue Change	0 %	-19.7 %	23.35 %	-53.64 %	20.59 %
Receivable Turnover Ratio (TTM)	2.94	5.36	23.44	22.57	5.96
IGC's Total Ranking	# 579	# 2546	# 2980	#	#
Accounts Receivable average collection period days	124	68	16	16	61
Seq. Receivable Change	1.13 %	1818.92 %	8.82 %	-17.07 %	-52.87 %
Seq. Revenue Change	23.77 %	-16.4 %	65.97 %	-41.77 %	-0.61 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 18
Healthcare Sector	# 51
Overall Market	# 579

Receivable Turnover Ratio Statistics
High	Average	Low
37.17	9.33	0.7
(Dec 31 2019)		(Jun 30 2017)

IGC Company Profile • Back to IGC Efficiency Comparisons • Compare IGC Receivables Turnover Ratio to its Competitors

Financial Statements
Igc Pharma Inc 's Accounts Receivable	$ 1 Millions	Visit IGC's Balance sheet
Igc Pharma Inc 's Sales TTM	$ 1 Millions	Visit IGC's Income Statement
Sources of IGC's Revenues		Visit IGC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IGC's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IGC's Growth Rates	IGC's Roa	IGC's Inventory Turnover Ratio	IGC's Dividend Comparisons
IGC's Profitability Ratios	IGC's Roi	IGC's Asset Turnover Ratio	IGC's Dividend Growth
IGC's Valuation Ratios	IGC's Roe	IGC's Financial Strength Ratios	IGC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Revvity Inc	4.15	$ 2,941.761 Millions	$ 708.139 Millions
Autolus Therapeutics Plc	4.10	$ 137.434 Millions	$ 33.520 Millions
Iovance Biotherapeutics inc	4.06	$ 378.983 Millions	$ 93.328 Millions
Medinotec Inc	4.05	$ 10.211 Millions	$ 2.524 Millions
Regenxbio Inc	4.03	$ 153.911 Millions	$ 38.148 Millions
Ironwood Pharmaceuticals inc	4.02	$ 400.296 Millions	$ 99.510 Millions
Hyperfine Inc	4.02	$ 18.537 Millions	$ 4.611 Millions
Upstream Bio Inc	4.00	$ 2.870 Millions	$ 0.717 Millions
Butterfly Network Inc	3.99	$ 123.715 Millions	$ 30.972 Millions
Vanda Pharmaceuticals Inc	3.96	$ 229.278 Millions	$ 57.866 Millions
Amgen Inc	3.96	$ 38,903.000 Millions	$ 9,822.000 Millions
Teva Pharmaceutical Industries Limited	3.89	$ 14,020.000 Millions	$ 3,608.000 Millions
Bridgebio Pharma Inc	3.88	$ 945.540 Millions	$ 243.561 Millions
Ligand Pharmaceuticals Incorporated	3.86	$ 253.827 Millions	$ 65.804 Millions
Ani Pharmaceuticals Inc	3.73	$ 1,041.343 Millions	$ 278.858 Millions
Biomarin Pharmaceutical Inc	3.70	$ 3,655.127 Millions	$ 987.382 Millions
Krystal Biotech Inc	3.57	$ 470.025 Millions	$ 131.556 Millions
Teleflex Incorporated	3.53	$ 1,283.675 Millions	$ 363.840 Millions
Ars Pharmaceuticals Inc	3.18	$ 122.136 Millions	$ 38.401 Millions
Coherus Oncology inc	3.18	$ 53.639 Millions	$ 16.870 Millions
Axsome Therapeutics Inc	3.16	$ 865.268 Millions	$ 274.025 Millions
Phathom Pharmaceuticals Inc	3.02	$ 274.881 Millions	$ 90.969 Millions
Adc Therapeutics Sa	2.91	$ 84.873 Millions	$ 29.154 Millions
Regeneron Pharmaceuticals Inc	2.64	$ 16,896.200 Millions	$ 6,404.025 Millions
Electromed Inc	2.60	$ 74.561 Millions	$ 28.646 Millions
Profound Medical Corp	2.54	$ 23.627 Millions	$ 9.307 Millions
Abcellera Biologics Inc	2.36	$ 67.858 Millions	$ 28.783 Millions
Arbutus Biopharma Corp	2.02	$ 181.490 Millions	$ 89.727 Millions
Ocular Therapeutix Inc	1.73	$ 50.384 Millions	$ 29.162 Millions
Heron Therapeutics Inc	1.71	$ 149.458 Millions	$ 87.396 Millions

Date modified: 2026-11-07T13:18:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.